Novel interactions of Slo1 channel and Thromboxane A2 receptor in blood vessels
血管中 Slo1 通道和血栓素 A2 受体的新相互作用
基本信息
- 批准号:7695542
- 负责人:
- 金额:$ 65.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAortaArteriesBindingBiochemistryBlood VesselsCalcium-Activated Potassium ChannelCardiovascular DiseasesCardiovascular PhysiologyCardiovascular systemCellsCharacteristicsComplexCoronaryCoronary arteryCoupledCouplingDataDevelopmentEctopic ExpressionEquilibriumEventFamilyFigs - dietaryFluorescence MicroscopyG-Protein-Coupled ReceptorsGTP-Binding ProteinsGoalsHealthHumanHypertensionKineticsKnowledgeLaboratoriesLeadLeftLinkLipid BilayersMacromolecular ComplexesMediatingMembraneMembrane ProteinsMethodsModelingMolecularMolecular BiologyMuscle CellsMyocardial InfarctionNaturePhysiologicalPhysiologyPlayProbabilityProceduresProstaglandinsProteinsRattusReceptor ActivationRecombinantsRegulationRhodopsinRoleSignal TransductionSmooth MuscleStrokeSystemTestingThromboxane A2Thromboxane A2 ReceptorTransmembrane DomainVasoconstrictor AgentsVasodilationVasodilator AgentsWorkanalogbasedesigndimerdisorder preventionextracellularlarge-conductance calcium-activated potassium channelsmembermimeticsnew therapeutic targetnovelprotein activationpublic health relevancereceptorreconstitutionresearch studytumorigenesisvasoconstrictionvoltage
项目摘要
Our long term goal is to obtain an integral view of the mechanisms by which Thromboxane A2-
prostanoid receptor (TPR) and the large conductance Ca2+-activated K+
channel (MaxiK, BK) interact
with each other to regulate vascular function. TPR and MaxiK play significant roles in determining vascular
health. In addition, both proteins are known to be involved in the modulation of tumorigenesis and myocardial
infarction. In coronary arteries, TPR are activated by the prostanoid thromboxane A2 (TXA2) leading to
powerful vasoconstrictions; while MaxiK channel aided by its β1 subunit can fine tune arterial tone determined
by the degree of channel activity. Our early work showed that TXA2 mimetic U46119 inhibits MaxiK channel
activity in membranes from coronary smooth muscle reconstituted in lipid bilayers, which suggested a strong
functional association between both TPR and MaxiK that endured dissociative reconstitution procedures.
Recent preliminary experiments also show that: 1) TPR modulates MaxiK pore-forming α subunit (Slo1) via
a novel mechanism that is G-protein independent, where MaxiK channel activity can be reduced by the
specific TPR agonist U46619, 2) TPR and MaxiK channel subunits form heteromultimeric complexes in
native arteries and in expression systems, 3) TPR and MaxiK channel functional coupling occurs in native
human coronary arterial myocytes and can be reproduced after ectopic expression of TPR and Slo1,
and 4) agonist-stimulation enhances TPR and Slo1 association. Here, we will test the hypothesis that
agonist stimulation changes TPR-Slo1-β1 associations resulting in Slo1 channel inhibition. The specific aims
are to: 1. Unravel the molecular mechanism(s) of Slo1 channel inhibition by agonist (U46619)- activated
TPR, and 2. Define the role of β1 subunit in agonist-TPR-Slo1 channel inhibition. Experiments will be
performed using modern approaches such as biochemistry, molecular biology, and opto-biophysical methods
including fluorescence microscopy at the diffraction limit. Because of the broad impact of MaxiK and TPR in
mammalian physiology, the knowledge derived from these studies may provide new opportunities for the
prevention of disease not only in the cardiovascular system but in other systems as well.
我们的长期目标是获得血栓素A2-
前列腺素受体(TPR)和大电导Ca ~(2+)激活的K ~+
通道(MaxiK,BK)相互作用
来调节血管功能TPR和MaxiK在血管生成中起重要作用,
健康此外,已知这两种蛋白质都参与肿瘤发生和心肌细胞凋亡的调节。
梗塞在冠状动脉中,TPR被前列腺素类血栓烷A2(TXA 2)激活,导致
强有力的血管收缩;而MaxiK通道在其β1亚基的帮助下可以微调动脉张力,
取决于渠道活动的程度。我们的前期工作表明TXA 2模拟物U46119抑制MaxiK通道,
冠状动脉平滑肌膜在脂质双层中重建的活性,这表明
TPR和MaxiK之间的功能关联经受分离重建程序。
最近的初步实验还表明:1)TPR通过以下途径调节MaxiK成孔α亚基(Slo 1)
一种不依赖于G蛋白的新机制,其中MaxiK通道活性可以通过
特异性TPR激动剂U46619,2)TPR和MaxiK通道亚基在细胞内形成异多聚体复合物,
天然动脉和表达系统中,3)TPR和MaxiK通道功能偶联发生在天然动脉中,
人冠状动脉心肌细胞,并可在TPR和Slo 1异位表达后复制,
和4)激动剂刺激增强TPR和Slo 1缔合。在这里,我们将测试假设,
激动剂刺激改变TPR-Slo 1-β1缔合,导致Slo 1通道抑制。具体目标
1.揭示激动剂(U46619)激活的Slo 1通道抑制的分子机制
TPR和2.明确β1亚基在激动剂-TPR-Slo 1通道抑制中的作用。实验将
使用生物化学、分子生物学和光生物物理方法等现代方法进行
包括衍射极限的荧光显微术。由于MaxiK和TPR在
哺乳动物生理学,从这些研究中获得的知识可能为研究哺乳动物生理学提供新的机会。
不仅预防心血管系统的疾病,也预防其他系统的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ENRICO STEFANI其他文献
ENRICO STEFANI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ENRICO STEFANI', 18)}}的其他基金
Novel interactions of Slo1 channel and Thromboxane A2 receptor in blood vessels
血管中 Slo1 通道和血栓素 A2 受体的新相互作用
- 批准号:
7851419 - 财政年份:2009
- 资助金额:
$ 65.39万 - 项目类别:
Revealing Cardiovascular Stress Regulation beyond the Diffraction Limit
揭示超越衍射极限的心血管压力调节
- 批准号:
7410118 - 财政年份:2007
- 资助金额:
$ 65.39万 - 项目类别:
Revealing Cardiovascular Stress Regulation beyond the Diffraction Limit
揭示超越衍射极限的心血管压力调节
- 批准号:
7788195 - 财政年份:2007
- 资助金额:
$ 65.39万 - 项目类别:
Revealing Cardiovascular Stress Regulation beyond the Diffraction Limit
揭示超越衍射极限的心血管压力调节
- 批准号:
8065410 - 财政年份:2007
- 资助金额:
$ 65.39万 - 项目类别:
Revealing Cardiovascular Stress Regulation beyond the Diffraction Limit
揭示超越衍射极限的心血管压力调节
- 批准号:
7251721 - 财政年份:2007
- 资助金额:
$ 65.39万 - 项目类别:
Revealing Cardiovascular Stress Regulation beyond the Diffraction Limit
揭示超越衍射极限的心血管压力调节
- 批准号:
7586132 - 财政年份:2007
- 资助金额:
$ 65.39万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 65.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 65.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 65.39万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 65.39万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 65.39万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 65.39万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 65.39万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 65.39万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 65.39万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 65.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)